Promising combo tackles rare sarcomas in early trial
NCT ID NCT03123276
First seen Feb 21, 2026 · Last updated May 15, 2026 · Updated 6 times
Summary
This early-phase study tested a combination of two drugs—pembrolizumab (an immunotherapy) and gemcitabine (a chemotherapy)—in 25 people with rare soft tissue sarcomas (leiomyosarcoma or undifferentiated pleomorphic sarcoma) that had spread or couldn't be removed. The main goal was to find a safe dose and see how well the treatment worked. While the approach aims to control the disease, it is not a cure, and ongoing management is expected.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Royal Marsden
London, United Kingdom
Conditions
Explore the condition pages connected to this study.